BioSpace News Archive

AlzeCure Pharma AB announced that the company is participating at the Vator Healthcare Innovation Summit at Epicenter Stockholm on October 7 at 10:20 CEST, where CEO Martin Jönsson will present the company’s latest developments.

All three tirzepatide doses led to more time in tight target range, improved glycemic variability and numerically less time in hypoglycemia compared to titrated insulin degludec in adults with type 2 diabetes in a continuous glucose monitoring sub-study1 of Eli Lilly and Company’s phase 3 SURPASS-3 clinical trial.

LEO Pharma A/S announced results showing adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference following two years of continuous treatment with tralokinumab.1 Interim findings from the Phase 3 ECZTEND trial were shared as an oral presentation during the European Academy of Dermatology and Venereology Congress 2021.

Immunic, Inc., a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced enrollment of the first patient in its phase 2 CALLIPER trial of lead asset IMU-838, the company’s selective oral DHODH inhibitor, in patients with progressive multiple sclerosis.

Genenta Science, a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announces the appointment of Barbara Regonini to the newly created post of Financial Director.

Merck, known as MSD outside the United States and Canada, and Acceleron Pharma Inc., a publicly traded biopharmaceutical company, announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Acceleron for $180 per share in cash for an approximate total equity value of $11.5 billion.

uniQure N.V. today announced its participation in the following upcoming investor and scientific conferences: Chardan’s 5th Annual Genetic Medicines Conference, October 4 - 5, 2021

Synairgen plc, the drug discovery, development and commercialisation company, announces its unaudited interim results for the six months ended 30 June 2021.

Seqster PDM, Inc. (“Seqster”), the pioneer in patient-centric healthcare data technology, announced today their strategic collaboration with BioIntelliSense, Inc, a clinical intelligence platform company, to combine its continuous health monitoring data services with contextual Electronic Health Record (EHR) and genomic data to enable remote patient monitoring, stratification and risk management.

Leading U.S. surgeons and hospitals complete first commercial cases with NuVasive’s integrated enabling technology platform for spine surgery